Subcutaneous Immunization with Unaltered Axenic Malaria Parasite Liver Stages Induces Sterile Protection against Infectious Sporozoite Challenge

Vaccines (Basel). 2022 Nov 8;10(11):1884. doi: 10.3390/vaccines10111884.

Abstract

Host cell-free, axenic development of liver stages (LS) of the malaria parasite has been demonstrated. Here we explored axenic liver stages as a novel live whole parasite malaria vaccine platform, which is unaltered and not prone to human-error, compared to the immunization with live-attenuated sporozoites that must be done intravenously. We show that in contrast to live sporozoites, axenic LS are not infectious to the immunized host. Subcutaneous immunizations of mice with Plasmodium yoelii axenic LS, developed from wild-type (WT) sporozoites or WT sporozoites expressing enhanced-GFP, conferred sterile protection against P. yoelii infectious sporozoite challenge. Thus, axenic liver stages of P. falciparum and P. vivax might constitute an attractive alternative to live sporozoite immunization.

Keywords: Plasmodium yoelii; axenic liver stage; malaria; subcutaneous immunization; vaccine.

Grants and funding

This work was funded by TUBITAK 1001 grant (Project No:119Z409) to A.S.I.A. from the Scientific and Technological Research Council of Turkey.